GRI Bio【GRI】銘柄情報

GRI Bio Inc (GRI) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

2.25

( -2.60% )

買値

1.71

売値

2.81

出来高

51,056

2.20 日の範囲 2.33

0.183 52 週間の範囲 6.70

時価総額

3.251M

前日終値

2.31

始値

2.33

時刻

2.23

最終取引時間

財務取引量

US$ 114,472

VWAP

2.2421

平均取引量 (3 か月)

US$ 85,713

発行済株式数

1,445,029

配当利回り

PER

-0.08

1 株当たり利益 (EPS)

-27.02

歳入

純利益

-10.91M

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natu... GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.gribio.com

本社

La Jolla, United States

設立

2026

GRI Bio Inc is listed in the Healthcare sector of the ナスダック市場 with ticker GRI. The last closing price for GRI Bio was US$2.31. Over the last year, GRI Bio shares have traded in a share price range of US$ 0.183 to US$ 6.70.

GRI Bio currently has 1,445,029 shares in issue. The market capitalisation of GRI Bio is US$3.25 million. GRI Bio has a price to earnings ratio (PE ratio) of -0.08.

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register...

Form 8-K - Current report

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.16	7.65550239234	2.09	2.35	1.99	99267	2.21644248	CS
4	0.11	5.14018691589	2.14	2.35	1.97	50878	2.15336637	CS
12	-0.37	-14.1221374046	2.62	2.77	1.97	86212	2.34760385	CS
26	1.705	312.844036697	0.545	6.7	0.183	1129498	0.83881828	CS
52	0.93	70.4545454545	1.32	6.7	0.183	981290	1.24206038	CS
156	-3.79	-62.7483443709	6.04	11.12	0.183	942146	1.13089268	CS
260	-10.95	-82.9545454545	13.2	13.33	0.183	904073	1.14147797	CS